ADAR1和HMGA2在甲状腺乳头状癌中的表达及临床意义分析

Expression and Clinical Significance of ADAR1 and HMGA2 in Papillary Thyroid Carcinoma

目的:研究ADAR1和HMGA2在甲状腺乳头状癌(papillary thyroid carcinoma, PTC)中的表达变化情况,并探究与临床特征的关联。方法:收集2022年6月~2023年3月就诊于青岛大学附属医院行手术切除,经病理确诊为甲状腺乳头状癌患者的癌组织和癌旁组织并收集相关临床资料。应用免疫组化等分子方法检测60对PTC癌组织及癌旁组织中ADAR1和HMGA2的表达情况,并分析探讨二者与临床特征的关联。结果:1) RT-qPCR、Western-blot及免疫组化实验结果均表明在甲状腺乳头状癌组织中ADAR1和HMGA2的表达量明显高于癌旁组织,组间差异具有统计学意义(P r = 0.437, P = 0.015)。结论:1) ADAR1和HMGA2在PTC组织中的表达上调,表明二者可能为PTC发生发展的促癌因素,表达的上调预示着更高的恶性程度及较差预后。2) ADAR1和HMGA2在PTC发生发展中可能存在协同作用的关系,具体作用机制有待进一步研究。

Objective: To investigate the expression changes of ADAR1 and HMGA2 in Papillary thyroid carcinoma, and explore their relationship with clinical features. Methods: Collected cancerous and para-cancerous tissues of patients diagnosed with papillary thyroid carcinoma after surgical resection in Affiliated Hospital of Qingdao University from June 2022 to March 2023 and related clinical data were collected. Immunohistochemical methods were used to detect the expression of ADAR1 and HMGA2 in 60 pairs of PTC cancer tissues and adjacent tissues, and to analyze the relationship between them and clinical features. Results: 1) The results of RT-qPCR, Western-blot and immunohistochemistry showed that the expression levels of ADAR1 and HMGA2 in papillary thyroid carcinoma tissues were significantly higher than those in adjacent tissues, and the differences between groups were statistically significant (P P = 0.015). Conclusion: 1) The up-regulated expression of ADAR1 and HMGA2 in PTC tissues indicates that they may be cancer-promoting factors in the occurrence and development of PTC, and the up-regulated expression predicts higher malignant degree and poor prognosis. 2) ADAR1 and HMGA2 may have a synergistic relationship in the occurrence and development of PTC, and the specific mechanism of action needs to be further studied.